791 related articles for article (PubMed ID: 30414038)
1. Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study.
Votanopoulos KI; Mazzocchi A; Sivakumar H; Forsythe S; Aleman J; Levine EA; Skardal A
Ann Surg Oncol; 2019 Jan; 26(1):139-147. PubMed ID: 30414038
[TBL] [Abstract][Full Text] [Related]
2. Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study.
Votanopoulos KI; Forsythe S; Sivakumar H; Mazzocchi A; Aleman J; Miller L; Levine E; Triozzi P; Skardal A
Ann Surg Oncol; 2020 Jun; 27(6):1956-1967. PubMed ID: 31858299
[TBL] [Abstract][Full Text] [Related]
3. Organoid Platform in Preclinical Investigation of Personalized Immunotherapy Efficacy in Appendiceal Cancer: Feasibility Study.
Forsythe SD; Erali RA; Sasikumar S; Laney P; Shelkey E; D'Agostino R; Miller LD; Shen P; Levine EA; Soker S; Votanopoulos KI
Clin Cancer Res; 2021 Sep; 27(18):5141-5150. PubMed ID: 34210684
[TBL] [Abstract][Full Text] [Related]
4. Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer.
Xie BY; Wu AW
Chin Med J (Engl); 2016 Oct; 129(20):2469-2475. PubMed ID: 27748340
[TBL] [Abstract][Full Text] [Related]
5. Establishment of 2.5D organoid culture model using 3D bladder cancer organoid culture.
Abugomaa A; Elbadawy M; Yamanaka M; Goto Y; Hayashi K; Mori T; Uchide T; Azakami D; Fukushima R; Yoshida T; Shibutani M; Yamashita R; Kobayashi M; Yamawaki H; Shinohara Y; Kaneda M; Usui T; Sasaki K
Sci Rep; 2020 Jun; 10(1):9393. PubMed ID: 32523078
[TBL] [Abstract][Full Text] [Related]
6. In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening.
Mazzocchi AR; Rajan SAP; Votanopoulos KI; Hall AR; Skardal A
Sci Rep; 2018 Feb; 8(1):2886. PubMed ID: 29440675
[TBL] [Abstract][Full Text] [Related]
7. Personalized Identification of Optimal HIPEC Perfusion Protocol in Patient-Derived Tumor Organoid Platform.
Forsythe SD; Sasikumar S; Moaven O; Sivakumar H; Shen P; Levine EA; Soker S; Skardal A; Votanopoulos KI
Ann Surg Oncol; 2020 Dec; 27(13):4950-4960. PubMed ID: 32632882
[TBL] [Abstract][Full Text] [Related]
8. Patient-Specific Sarcoma Organoids for Personalized Translational Research: Unification of the Operating Room with Rare Cancer Research and Clinical Implications.
Forsythe SD; Sivakumar H; Erali RA; Wajih N; Li W; Shen P; Levine EA; Miller KE; Skardal A; Votanopoulos KI
Ann Surg Oncol; 2022 Nov; 29(12):7354-7367. PubMed ID: 35780216
[TBL] [Abstract][Full Text] [Related]
9. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.
Ubink I; Bolhaqueiro ACF; Elias SG; Raats DAE; Constantinides A; Peters NA; Wassenaar ECE; de Hingh IHJT; Rovers KP; van Grevenstein WMU; Laclé MM; Kops GJPL; Borel Rinkes IHM; Kranenburg O
Br J Surg; 2019 Sep; 106(10):1404-1414. PubMed ID: 31197820
[TBL] [Abstract][Full Text] [Related]
10. Organoid Cultures Derived From Patients With Papillary Thyroid Cancer.
Chen D; Tan Y; Li Z; Li W; Yu L; Chen W; Liu Y; Liu L; Guo L; Huang W; Zhao Y
J Clin Endocrinol Metab; 2021 Apr; 106(5):1410-1426. PubMed ID: 33524147
[TBL] [Abstract][Full Text] [Related]
11. Complete cytoreduction offers longterm survival in patients with peritoneal carcinomatosis from appendiceal tumors of unfavorable histology.
Omohwo C; Nieroda CA; Studeman KD; Thieme H; Kostuik P; Ross AS; Holter DR; Gushchin V; Merriman B; Sardi A
J Am Coll Surg; 2009 Sep; 209(3):308-12. PubMed ID: 19717034
[TBL] [Abstract][Full Text] [Related]
12. Outcomes After Adjuvant Hyperthermic Intraperitoneal Chemotherapy for High-Risk Primary Appendiceal Neoplasms After Complete Resection.
Enomoto LM; Choudry MH; Bartlett DL; Totin L; Mann GN; Skitzki JJ; Perry KC; Votanopoulos KI; Levine EA; Shen P
Ann Surg Oncol; 2020 Jan; 27(1):107-114. PubMed ID: 31368017
[TBL] [Abstract][Full Text] [Related]
13. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
14. Organoids From Mucinous Appendiceal Adenocarcinomas as High-Fidelity Models for Individual Therapy.
Liu G; Xiao X; Xia Y; Huang W; Chen W; Xu J; Chen S; Wang H; Wei J; Li H; Shu M; Lu X; Zhang C; He Y
Front Med (Lausanne); 2022; 9():829033. PubMed ID: 35721089
[TBL] [Abstract][Full Text] [Related]
15. An Organoid-Based Preclinical Model of Human Gastric Cancer.
Steele NG; Chakrabarti J; Wang J; Biesiada J; Holokai L; Chang J; Nowacki LM; Hawkins J; Mahe M; Sundaram N; Shroyer N; Medvedovic M; Helmrath M; Ahmad S; Zavros Y
Cell Mol Gastroenterol Hepatol; 2019; 7(1):161-184. PubMed ID: 30522949
[TBL] [Abstract][Full Text] [Related]
16. Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy.
Narasimhan V; Wright JA; Churchill M; Wang T; Rosati R; Lannagan TRM; Vrbanac L; Richardson AB; Kobayashi H; Price T; Tye GXY; Marker J; Hewett PJ; Flood MP; Pereira S; Whitney GA; Michael M; Tie J; Mukherjee S; Grandori C; Heriot AG; Worthley DL; Ramsay RG; Woods SL
Clin Cancer Res; 2020 Jul; 26(14):3662-3670. PubMed ID: 32376656
[TBL] [Abstract][Full Text] [Related]
17. Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade mucinous carcinoma peritonei of appendiceal origin.
Munoz-Zuluaga CA; King MC; Ledakis P; Gushchin V; Sittig M; Nieroda C; Zambrano-Vera K; Sardi A
Eur J Surg Oncol; 2019 Sep; 45(9):1598-1606. PubMed ID: 31109821
[TBL] [Abstract][Full Text] [Related]
18. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
[TBL] [Abstract][Full Text] [Related]
19. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]